Acceleron Pharma Inc  

(Public, NASDAQ:XLRN)   Watch this stock  
Find more results for GEORGE A. NADER´┐Ż
30.02
-1.62 (-5.12%)
Jul 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.70 - 32.14
52 week 23.61 - 48.50
Open 32.00
Vol / Avg. 0.00/177,431.00
Mkt cap 1.04B
P/E     -
Div/yield     -
EPS -1.66
Shares 32.81M
Beta     -
Inst. own 96%
Aug 10, 2015
Q2 2015 Acceleron Pharma Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 23, 2015
Acceleron Pharma Inc at JMP Securities Life Sciences Conference
Jun 15, 2015
Acceleron Pharma Inc Conference Call and Webcast to Review New Luspatercept Data Presented at the 20th Congress of the European Hematology Association - Webcast
Jun 4, 2015
Acceleron Pharma Inc Annual Shareholders Meeting
Jun 1, 2015
Acceleron Pharma Inc at Jefferies Global Healthcare Conference
May 20, 2015
Acceleron Pharma Inc at UBS Global Healthcare Conference
May 12, 2015
Acceleron Pharma Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Acceleron Pharma Inc at Deutsche Bank Health Care Conference
May 7, 2015
Q1 2015 Acceleron Pharma Inc Earnings Release
May 7, 2015
Q1 2015 Acceleron Pharma Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -329.73% -350.32%
Operating margin -340.70% -379.06%
EBITD margin - -337.25%
Return on average assets -32.31% -33.07%
Return on average equity -38.70% -47.88%
Employees 83 -
CDP Score - -

Address

128 SYDNEY STREET
CAMBRIDGE, MA 02139
United States - Map
+1-617-6499200 (Phone)
+1-617-6499988 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acceleron Pharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company's research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. By combining its discovery and development know-how, including its knowledge of the TGF-b superfamily, and its internal protein engineering and manufacturing capabilities, the Company has built a discovery and development platform that has generated therapeutic candidates with new mechanisms of action. The Company has four internally discovered therapeutic candidates that are in clinical trials.

Officers and directors

Francois Nader M.D. Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
John L. Knopf Ph.D. President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Kevin F. McLaughlin Chief Financial Officer, Senior Vice President, Treasurer
Age: 58
Bio & Compensation  - Reuters
Steven D. Ertel Chief Operating Officer, Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Matthew L. Sherman M.D. Executive Vice President and Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Ravindra Kumar Ph.D Chief Scientific Officer, Vice President
Age: 55
Bio & Compensation  - Reuters
John D. Quisel J.D., Ph.D. Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Terrence C. Kearney Director
Age: 60
Bio & Compensation  - Reuters
Jean M. George Independent Director
Age: 57
Bio & Compensation  - Reuters
George S. Golumbeski Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters